Specifically, AS-IV was found to downregulate the protein expression of N-cadherin, α-SMA and TGF-β1, while upregulating the expression of E-cadherin, thereby inhibiting the EMT process and alleviating the pathological progression of liver fibrosis (Dai et al., 2022). Here, TGFB1 is linked to Hepatic fibrosis.